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Abstract Treating staphylococcal biofilm-associated infec-
tions is challenging. Based on the findings that compound 2
targeting the HK domain of Staphylococcus epidermidis
YycG has bactericidal and antibiofilm activities against staph-
ylococci, six newly synthesized derivatives were evaluated for
their antibacterial activities. The six derivatives of compound
2 inhibited autophosphorylation of recombinant YycG′ and
the IC50 values ranged from 24.2 to 71.2 μM. The derivatives
displayed bactericidal activity against planktonic
S. epidermidis or Staphylococcus aureus strains in the MIC
range of 1.5–3.1 μM. All the derivatives had antibiofilm
activities against the 6- and 24-h biofilms of S. epidermidis.
Compared to the prototype compound 2, they had less cyto-
toxicity for Vero cells and less hemolytic activity for human
erythrocytes. The derivatives showed antibacterial activities
against clinical methicillin-resistant staphylococcal isolates.
The structural modification of YycG inhibitors will assist the
discovery of novel agents to eliminate biofilm infections and
multidrug-resistant staphylococcal infections.
Keywords Staphylococcusepidermidis .Methicillin-resistant
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Introduction
Staphylococcus epidermidis and Staphylococcus aureus are
common pathogens in medical device biofilm-associated in-
fections (Knobloch et al. 2001; Yarwood et al. 2004). Their
ability to attach onto biomaterial surfaces of implanted med-
ical devices or to fragments of dead tissue and form biofilms
results in chronic and refractory infections (Otto 2012b) that
are resistant to antibiotics and to host defense clearance mech-
anisms (Spoering and Lewis 2001). S. epidermidis is a com-
mon cause of biofilm-associated infections, even though it is
less virulent than S. aureus (Giacometti et al. 2000; O’Gara
and Humphreys 2001). Biofilm-associated infections persist
until the implanted medical device is removed, resulting in
extra trauma and cost (Donlan and Costerton 2002; Kiran
et al. 2010). Up to 25 % of orthopedic implants are subject
to revision surgery due to biofilm infections (Mah and
O’Toole 2001; Otto 2012a).
Currently available antibiotics for the treatment of bacterial
infections are targeted at the planktonic cells, not the sessile
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cells in biofilms (Falsetta et al. 2012). Consequently, strategies
against staphylococcal biofilm infections include targeting the
systems regulating biofilm formation, such as two-component
systems or quorum sensing systems; degrading the matrix to
disperse the bacteria; developing a new generation of antibi-
otics; and adopting novel combinations of antimicrobial
agents (West and Stock 2001; Yarwood et al. 2004).
However, the mechanisms of multiple antibiotic resistance in
S. epidermidis and S. aureus biofilms are complex. The bio-
film matrix may decrease antibiotic diffusion into the biofilm
structure, causing the bacteria to have less exposure to the
antimicrobial compounds. Nutrient or oxygen depletion with-
in the biofilm causes the cells to have low metabolic activity
and a reduced growth rate, thus rendering biofilm bacteria
resistant to antibiotics (Aendekerk et al. 2005; Walters et al.
2003). Most existing antibiotics fail to adequately penetrate
the biofilm or have limited activity against surface-attached
cells and cells with low metabolic activity (Kiedrowski and
Horswill 2011). Vancomycin is regarded as an antibiotic of last
resort against methicillin-resistant S. aureus (MRSA),
methicillin-resistant S. epidermidis (MRSE), and other multi-
ple antibiotic-resistant infections caused by gram-positive bac-
teria, but it has no significant effect on the bacteria in a biofilm
(Qin et al. 2006; Roper et al. 2000). Daptomycin and linezolid
are now available for biofilm-associated infections caused by
staphylococci, but neither was found to be bactericidal against
biofilm-embedded bacteria (Parra-Ruiz et al. 2012). More
novel drugs are urgently required to combat staphylococcal
biofilm-associated infections and the targeting of a bacterial
two-component system (TCS) is the approach taken here.
A TCS, composed of a histidine kinase (HK) and a re-
sponse regulator (RR), serves as a basic stimulus-response
coupling mechanism by which bacteria sense and respond to
environmental changes. TCSs have been found in bacteria,
fungi, and plants, but not in vertebrates (Barrett and Hoch
1998; West and Stock 2001). YycFG is an essential TCS that
is highly conserved in gram-positive bacteria with a low G+C
content (Dubrac et al. 2007). It plays important roles in the
growth, cell wall metabolism, and biofilm formation of path-
ogenic staphylococcal species (Winkler and Hoch 2008). It
has been suggested that YycG or YycF may serve as potential
targets for the development of novel antimicrobial agents
(Fukushima et al. 2011; Szurmant et al. 2005; Turck and
Bierbaum 2012).
We have previously described two YycG inhibitors that
target the HK domain of S. epidermidis YycG and show
bactericidal and antibiofilm activities against S. epidermidis
and S. aureus. One of the two leading compounds is compound
2: {2-{4-{3-(2-ethylphenyl)-2-[(2-ethylphenyl)imino]-4-
oxothiazolidin-5-ylidene}methyl}-2-methoxyphenoxy}acetic
acid (Huang et al. 2012; Qin et al. 2006). To enhance the
antimicrobial activities of compound 2 and reduce the toxicity
to mammalian cells, the structure was optimized in a series of
derivatives by substituting different functional groups (fluorine
group, thiophene ring, etc.) while keeping the core structure
intact (Dan Zhao et al. 2013). Six out of 56 newly synthesized
derivatives of compound 2 were selected for their anti-
Staphylococcus activity. In this study, we evaluated the antimi-
crobial activities of the six derivatives, including in vitro min-
imal inhibitory concentration (MIC), bactericidal activity,
antibiofilm efficacy, YycG phosphorylation-inhibiting activity,
potential toxicity, and in vivo effectiveness in a rabbit subcuta-
neous S. epidermidis biofilm infection model.
Materials and methods
Ethics statement
All procedures performed on rabbits were conducted accord-
ing to relevant national and international guidelines (the
Regulations for the Administration of Affairs Concerning
Experimental Animals, China) and were approved by the
Institutional Animal Care and Use Committee (IACUC) of
Shanghai Medical College, Fudan University (IACUC
Animal Project Number: 20110630).
Bacterial strains, media, and derivatives of compound 2
Bacterial strains S. epidermidis ATCC 12228 (nonbiofilm
forming), S. epidermidis ATCC 35984 (biofilm forming),
S. aureusATCC 49230, and S. aureusATCC 25923 were from
the American Type Culture Collection (ATCC, Manassas,
USA) and were cultured in tryptic soy broth medium (TSB;
Oxoid Ltd., Basingstoke, England). Ten clinical methicillin-
resistant staphylococcal isolates, five MRSA isolates and five
MRSE isolates, were collected from Huadong Teaching
Hospital in Shanghai. Escherichia coli ATCC 25922 was
grown in Luria-Bertani (LB) broth. The six compounds used
in this study (H2-38, H2-39, H2-57, H2-60, H2-74, and H2-81)
were screened from 56 derivatives of compound 2 in which the
functional groups were modified, but the thiazolidine core
structure was unchanged. The compounds were synthesized
by Nanjing University of Technology. To generate the deriva-
tive compounds, halogen atoms were introduced into 4-
thiazolidinone compounds that contained carboxylic acid moi-
eties of phenoxy-acetic acid, (5-vinyl-furan-2-yl)-benzoic acid
or (5-vinyl-thiophene-2-yl)-benzoic acid. The derivatives were
dissolved in dimethyl sulfoxide (DMSO; Amresco, USA) to
200 mM for use as stock solutions. The structures and system-
atic names of the derivatives are listed in Fig. 1.
MIC and MBC assays
MICs of the derivatives for S. epidermidis and S. aureus were
determined by the broth dilution method according to the
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National Committee for Clinical Laboratory (NCCLS) recom-
mendations (Turnidge and Bordash 2007). Twofold dilutions
of the derivatives in tubes containing 4 ml of Mueller-Hinton
broth (MH, Sigma, Germany) were made to concentrations
from 200 to 0.39 μM. Overnight cultures of the bacteria were
adjusted to the 0.5 McFarland standards and inoculated 1:200
into the MH broth and then incubated at 37 °C for 16–20 h.
The lowest concentration inhibiting visible growth of the
bacteria was recorded as minimal inhibitory concentration
(MIC). For the minimal bactericidal concentration (MBC)
assay, a 100-μl aliquot from the MIC assay tubes with no
visible turbidity was spread on freshly prepared MH agar
plates and incubated at 37 °C for 24 h, and the colonies were
counted. The MBC of the derivatives was determined as the
lowest concentration of the derivative required to allow less
than five colonies to grow on each plate (Qin et al. 2006).
Inhibition of YycG′ autophosphorylation
Recombinant YycG (YycG′, amino acids 370–610) was
prepared by expressing the HATPase_c and HisKA domains
of YycG in E. coli BL21 (DE3). In brief, the sequence
coding for YycG′ was amplified from the genome of
S. epidermidis ATCC 35984 by PCR and cloned into the
pET28a (+) vector, which inserts a GB1 tag (B1 domain of
protein G, 56 residues) to make the recombinant fusion
protein highly soluble and stable. The recombinant YycG′
protein was fused to the GB1 tag at its N-terminus end,
expressed in E. coli BL21 (DE3) and purified by Ni2+
affinity chromatography on a Ni-NTA column (Qiagen,
Germany). The purified YycG′ was cleaved by TEV protease
and further purified by Ni-NTA and Superdex 75 gel filtration
columns (GE Healthcare, USA).
The Kinase-Glo™ Luminescent Kinase Assay (Promega,
Madison, WI, USA) was used to measure the inhibitory
activities of the derivatives against the autophosphorylation
activity of the recombinant YycG′ following the manufac-
turer’s recommendation. The derivatives were serially diluted
from 200 to 1.6 μMwith reaction buffer (40 mM Tris pH 8.0,
20 mM MgCl2, and 0.1 mg/ml BSA). Recombinant YycG′
(0.02 μg/μl) and diluted derivative were added into a 96-well
plate and incubated at 25 °C for 30 min, and then 4 μM ATP
was added into each well and incubated for another 30 min.
Finally, 50 μl Kinase-Glo™ Reagent containing luciferase
(kinase) and D-luciferin was added. The luminescent signal
generated by luciferase was in proportion to the amount of
ATP remaining in the reaction. Luminescence was detected by
a Perkin Elmer Victor X5 luminescence plate reader, and the
intensity was recorded as relative light units (RLU). The wells
containing ATP and Kinase-Glo™ without YycG′ and deriv-
atives or containing YycG′ plus ATP and Kinase-Glo™ with-
out the derivatives were used as the controls. The percentage
inhibition of protein phosphorylation (Rp) by the derivatives
was calculated as follows:
Rp ¼
RLU YycG’ þ derivativeþ ATPþ KinaseGloTM
 
 RLU YycG’ þ ATPþ KinaseGloTM
 
RLU ATPþ KinaseGloTM  RLU YycG’ þ ATPþ KinaseGloTM
   100
Fig. 1 The structures of the thiazolidione derivatives. Based on the
thiazolidione core structure of compound 2 {2-{4-{3-(2-ethylphenyl)-
2-[(2-ethylphenyl)imino]-4-oxothiazolidin-5-ylidene}methyl}-2-
methoxyphenoxy}acetic acid, six derivatives were designed and synthe-
sized by modifying the functional groups through cyclization, aldol
condensation, substitution and hydrolyzation reactions. H2-38,
3-{5-{{3-(4-chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-
5-ylidene}methyl}furan-2-yl}benzoic acid; H2-39, 4-{5-{{3-(4-
chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-5-
ylidene}methyl}furan-2-yl}benzoic acid; H2-57, 4-{5-{{3-(4-
ch lo ropheny l ) -2 - [ (4 -pheny l ) imino] -4 -oxo th i azo l id in -5 -
ylidene}methyl}furan-2-yl}benzoic acid; H2-60, 4-{5-{{3-(4-
fluorophenyl)-2-[(4-fluorophenyl)imino]-4-oxothiazolidin-5-
ylidene}methyl}thiophene-2-yl}benzoic acid; H2-74, 2-{4-{[3-(4-
chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-5-
ylidene}methyl}phenoxy}acetic acid; H2-81, 4-{5-{{3-(4-
f l uo ropheny l ) -2 - [ (4 -pheny l ) im ino ] -4 -oxo th i azo l i d in -5 -
ylidene}methyl}thiophene-2-yl}benzoic acid
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The concentration of a derivative required to inhibit half of
the autophosphorylation of recombinant YycG′ (half maximal
inhibitory concentration, IC50) was calculated with Origin 8.0
software (Origin Lab, Northampton, USA). Three indepen-
dent assays were carried out, and each was performed in
quadruplicate.
Microtiter plate assay of S. epidermidis biofilms
The effects of the derivatives on immature (6-h-old) biofilms
andmature (24-h-old) biofilms of S. epidermidisATCC 35984
were detected by using a semiquantitative microtiter plate
assay (Stepanovic et al. 2007). An overnight culture of bacte-
ria was inoculated 1:200 into TSB medium containing 0.25 %
glucose and statically incubated in a polystyrene 96-well plate
(200 μl per well) at 37 °C for 6 or 24 h. The medium
containing any nonadherent bacteria was then removed, and
serial dilutions of derivatives in 200 μl fresh TSB were added
to the wells and incubated for another 16 h at 37 °C. The wells
were then washed gently three times with phosphate buffered
saline (PBS), air-dried, fixed with methanol, and stained with
2 % (w/v) crystal violet. The staining was visually assessed
and scanned at 570 nm using a 96-well plate spectrophotom-
eter (DTX880, Beckman Coulter, USA), and the minimal
biofilm eradication concentration (MBEC) was measured
(Ceri et al. 1999).
Observation of S. epidermidis biofilms by confocal laser
scanning microscopy
The effects of the derivatives on bacterial viability in mature
(24-h-old) biofilms of S. epidermidis ATCC 35984 were eval-
uated by a confocal laser scanning microscope (CLSM), with
Live/Dead staining (BacLight, Molecular Probes, USA) for
assessing bacterial viability (Qin et al. 2006). A diluted over-
night culture of the bacteria was inoculated into cell culture
glass bottom dishes (WPI, USA) and incubated at 37 °C for
24 h. After removal of the suspension cultures, the derivatives
in fresh TSB at fourfold MIC concentration were added and
incubated at 37 °C for 16 h. The biofilms were washed with
PBS and stained with SYTO9 and propidium iodide (PI), both
of which were used at a concentration of 1 μM. SYTO9-
stained live cells and PI-stained cells dead in biofilms were
visualized by a Leica TCS SP5 confocal laser scanning mi-
croscope with a ×63 1.4-NA oil immersion objective. Three-
dimensional biofilm images were created by IMARIS 7.0.0
software (Bitplane).
Observation of S. epidermidis biofilms by scanning electron
microscopy
S. epidermidisATCC 35984 was statically incubated for 6 h in
polystyrene 96-well plates at 37 °C, then the diluted
derivatives H2-74 and H2-81 were added at concentrations
of 4×MIC in fresh TSB medium and incubated for another
16 h at 37 °C. After the incubation, the wells were washed
with PBS, fixed with glutaraldehyde (2.5 % in PBS) for 2 h,
and rinsed with PBS. All samples were mounted on SEM
sample stubs, sputtered with platinum, and observed under a
field emission scanning electron microscope (JSM-6700 F,
Japan).
Kinetics of killing planktonic S. epidermidis
An overnight culture of S. epidermidis ATCC 35984 was
inoculated into 20 ml of fresh MH broth at a 1:200 dilution
(106 CFU/ml). Concentrations of H2-74 or H2-81 from
0.38 μM (1/4×MIC) to 6.3 μM (4×MIC) were added and
incubated at 37 °C with shaking at 200 rpm for 12 h. Every
2 h, 100 μl of the culture was diluted and spread on agar
plates. Viable bacteria (CFU) were counted and the rate and
extent of killing were determined by plotting CFU/ml against
time (D’Arezzo et al. 2012; Lee et al. 2008). This experiment
was independently repeated three times.
Cytotoxicity and hemolytic activity of the derivatives
Vero 76 cells (African green monkey cells) were used to
determine the cytotoxicity of the derivatives with the Cell
Proliferation Kit I (MTT) (Roche, Indianapolis, USA). The
Vero cells were grown in Dulbecco’s modified Eagle’s medi-
um (DMEM), supplemented with 5 % fetal calf serum, 100
U/ml penicillin, 100 mg/ml streptomycin, and 2 mML-gluta-
mine. After culturing in 5 % CO2 at 37 °C for 48 h, the cells
were harvested and dispensed into 96-well cell culture plates
containing 5×104 cells per well in 100 μl. The cells were co-
incubated with serial twofold dilutions of derivatives from 200
to 6.25 μM (six different concentrations) for 24 h at 37 °C in
5 % CO2. Then, 10 μl of the MTT labeling reagent (final
concentration 0.5 mg/ml) was added to each well and incu-
bated for 4 h. The solubilization solution (100μl per well) was
added to dissolve the purple formazan salts generated in the
viable cells, and the absorbance of each well was measured at
595 nm. Cells treated with the solvent (0.1 % DMSO) were
used as a negative control and the cells cultured only with
DMEMmedium served as a blank control. The inhibitory rate
was calculated as follows:
Inhibitory rate% ¼ Ocontrol−ODtest
ODcontrol
 100
CC50 was defined as the concentration of the derivatives
that inhibited the Vero cell growth by 50% and was calculated
with the Origin v8.0 software (Origin Lab, Northampton,
USA) (Qin et al. 2006).
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The hemolytic activities of the derivatives on healthy
human erythrocytes were also determined. Healthy human
erythrocytes resuspended in normal saline (NS) at 5 % (v/v)
were co-incubated with the derivatives at final concentra-
tions of MIC, 4×MIC, or 200 μM for 1 h at 37 °C in 96-
well microtiter plates. The suspensions were centrifuged at
350g for 10 min and the supernatant (100 μl) was trans-
ferred to new wells and measured at 570 nm on a spectro-
photometer (Benchmark Microplate Reader; Bio-Rad,
Hercules, CA, USA). The percentage of hemolysis was
calculated by normalizing against the absorbance of eryth-
rocytes treated with 1 % Triton X-100, which caused
complete hemolysis; 0.1 % DMSO-treated cells were used
as a control (Miyoshi et al. 1997). The experiment was
performed in quadruplicate wells and repeated independently
three times.
Rabbit subcutaneous S. epidermidis biofilm infection model
To test the effectiveness in vivo of H2-74 and H2-81, 24-h
biofilms of S. epidermidis grown on polyethylene disks were
imbedded subcutaneously into the New Zealand White rab-
bits and treated with the derivatives for 72 h in a modifica-
tion of the method used previously (He et al. 2011). Disks
were cut from polyethylene 96-well plates (8 mm diameter,
1 mm thickness), sterilized with 75 % ethanol and placed in
a Petri dish (100 mm diameter). An overnight culture of
S. epidermidis ATCC 35984 (20 ml) was inoculated into the
dish and incubated at 37 °C for 24 h. The disks covered
with biofilms were then implanted subcutaneously in female
New Zealand White rabbits (2.0–2.5 kg) that had been
anesthetized with pentobarbital sodium (5 mg/kg i.v.). Four
incisions (10 mm) were made on the back of the rabbit
along the spine bilaterally after removal of fur, and the sub
cutis was carefully dissected to form a 2-cm×3-cm cavity.
Two biofilm-covered polyethylene disks were implanted into
each cavity, and to minimize the effect of between-animal
variation, four different treatments were given locally to
each rabbit.
The treatments were as follows: 1 ml of H2-74 (6.3 μM,
4×MIC) or H2-81 (6.3 μM, 4×MIC) dissolved in NS was
injected into the cavity locally after the biofilm-covered disks
were implanted and the incisions were sutured, and the same
dosages were administered at 24 and 48 h. Vancomycin
(128 mg/l) and 0.1 % DMSO were administered as the con-
trols. Twenty-four hours after the last treatment, the rabbits
were euthanized and the implants were taken out with sterile
forceps. Biofilms were scraped from the disks, and the viable
bacteria were determined by CFU counting, as previously
described (He et al. 2011). All animals were housed and used
in compliance with the guidelines of the Institute of Animal
Care and Use Committee, and the protocol was approved by
the committee.
Statistical analysis
Data from the rabbit model of S. epidermidis biofilm infection
were compared by one-way analysis of variance (ANOVA)
and Bonferroni’s multiple comparison test using the Origin
v8.0 software (Origin Lab, Northampton, USA). A p value
less than 0.05 was considered statistically significant.
Results
Six of our 56 synthesized derivatives of leading compound 2
(H2-38, H2-39, H2-57, H2-60, H2-74, and H2-81) had exhib-
ited lowMICs (≤3.1 μM) against S. epidermidisATCC 35984
(Huang et al. 2012; Qin et al. 2006) and were selected for
further investigation of antimicrobial and antibiofilm
activities.
Inhibition of YycG′ autophosphorylation
The inhibition effects of the six derivatives on the autophos-
phorylation activity of the purified recombinant YycG′ were
detected by using the Kinase-Glo™ Luminescent Kinase
Assay. The recombinant YycG′ hydrolyzed ATP for its auto-
phosphorylation in the reaction; the phosphorylation of YycG′
was inhibited when treated with the derivatives and the IC50
values of each derivatives were calculated. At a concentration
of 100 μM, H2-38, H2-39, H2-57, H2-60, H2-74, and H2-81
inhibited the enzymatic autophosphorylation of YycG′
(0.13 μM) by 61.8, 56.3, 59.7, 55.4, 53.9, and 79.2 %, re-
spectively. The IC50 values of the six derivatives ranged from
24.2 to 71.2 μM and the IC50 of the prototype compound 2
was 47.9 μM as shown in Table 1.
Antimicrobial activities of the derivatives
All six derivatives inhibited the growth of S. epidermidis
ATCC 35984 in MH broth; the MIC values of the derivatives
ranged from 1.6 to 3.1 μM, and the MBC ranged from 6.3 to
25 μM, while the MIC and MBC of compound 2 were much
higher which were 25 and 100 μM, respectively (Table 1).
The ratios of MIC/MBC values of most derivatives (H2-38,
H2-39, H2-57, H2-60, and H2-81) ranged from 1/2 to 1/8,
whereas for H2-74, the ratio reached 1/16.
According to the different bacteriostatic and bactericidal
activities of the derivatives, we chose H2-74 and H2-81 for
further assay and tested killing kinetics against planktonic
bacteria. In the initial treatment phase (from 2 to 6 h), at the
concentrations of 1/4MIC (0.38 μM) and 1/2MIC (0.75 μM),
H2-74 and H2-81 inhibited the growth of S. epidermidis, as
shown in Fig. 2. When treated with H2-74 at 2×MIC (3.1 μM
for 12 h, the viable cells were decreased to 3.2×103 CFU/ml
(Fig. 2a), while with H2-81 treatment at 2×MIC, the viability
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was decreased to less than 3×102 CFU/ml (Fig. 2b). When
treated with H2-81 at the concentration of 4×MIC (6.3 μM)
for 10 h, the viable cells decreased to fewer than 10 CFU/ml,
but for H2-74, more than 3.1×102 CFU/ml were left.
We further tested the antimicrobial activity of the six de-
rivatives on two S. aureus standard strains (S. aureus ATCC
49230 and S. aureusATCC25923) and ten clinical methicillin-
resistant staphylococcal strains (five MRSE and five MRSA
isolates). All six derivatives were able to inhibit the growth of
S. aureus in addition to S. epidermidis, and the MIC values
ranged from 1.6 to 6.3 μM (Table 2). They had no effect on
the growth of E. coli strain ATCC 25922 at 200 μM, which is
the highest concentration used in the present study.
Effect of the derivatives on S. epidermidis biofilms
The activities of the six derivatives on the both immature and
mature biofilms of S. epidermidis ATCC 35984 were
evaluated, and the MBEC was determined. When 6-h-old
(immature) biofilms on 96-well plates were treated for 12 h,
the six derivatives all inhibited biofilm formation. The MBEC
ranged from 6.3 to 50 μM, lower than that of compound 2;
H2-81 had the lowest MBEC and H2-74 the highest (Table 2).
When 24-h-old (mature) biofilms were treated, no difference
was found between the OD570 values of the treated and
untreated biofilms (data not shown).
When 6-h-old biofilms on the polystyrene bottomed plates
were treated with either H2-74 or H2-81 at a concentration of
4×MIC, few bacteria on the plates were observed using
scanning electronmicroscopy.When treated with vancomycin
(128 mg/l), the morphology of the biofilms was similar to that
treated with 0.1 % DMSO as a negative control (Fig. 3).
When the bactericidal activity of the derivatives on mature
(24-h-old) biofilms of S. epidermidis on glass was assessed by
confocal microscopy with Live/Dead staining (CLSM), all six
derivatives showed bactericidal activities at 4×MIC. H2-81
Table 1 Biological activities of the six derivatives of compound 2




Compound 2 519 25 100.0 1/4 100.0 47.9±5.3 50 2.31±0.35 5.24±0.21
H2-38 534.02 1.5 12.5 1/8 12.5 41.4±3.4 >200 0.14±0.03 0.28±0.03
H2-39 534.02 1.5 12.5 1/8 12.5 59.8±1.4 >200 0.12±0.03 0.41±0.05
H2-57 500.06 3.1 12.5 1/4 12.5 47.1±1.5 >200 0.14±0.03 0.16±0.04
H2-60 518.06 1.5 12.5 1/8 12.5 63.7±2.3 >200 0.52±0.06 0.84±0.03
H2-74 498.02 1.5 25.0 1/16 50.0 71.2±4.9 >200 0.14±0.03 0.42±0.03
H2-81 500.07 1.5 6.3 1/4 6.3 24.2±1.2 >200 0.06±0.09 0.10±0.03
a Stock solutions (200 mM) of the derivatives were prepared in DMSO, and 200 μM was the highest concentration used in this study
bMIC,MBC, andMBEC represent minimal inhibitory concentration, minimal bactericidal concentration, andminimal biofilm eradication concentration
of the derivatives against S. epidermidis ATCC 35984
c IC50 represents half maximal inhibitory concentration of the derivatives, which is the concentration needed to inhibit half of the autophosphorylation of
recombinant YycG′ determined by the Kinase-Glo™ Luminescent Kinase Assay kit
d CC50 represents the derivative concentration that produces 50 % cytotoxicity effects on Vero cells. At 200 μM, cytotoxicity of the derivatives on the
Vero cells was less than 3 % determined by the MTT assay with the Cell Proliferation Kit
e Hemolytic activities of the derivatives at the MICs and 200 μM were detected on healthy human erythrocytes
Fig. 2 The kinetics of H2-74 and H2-81 action against S. epidermidis
ATCC 35984. The bacteria were cultured with H2-74 (a) or H2-81 (b) at
1/4×MIC, 1/2×MIC, 1×MIC, 2×MIC, and 4×MIC in 20 ml of fresh
MH broth, at 37 °C for 12 h. Every 2 h, viable bacteria (CFU) were
counted. The bacterial growth inhibition/killing was determined by plot-
ting viable colony counts (CFU/ml) against time. The results are from
three separate experiments and presented as the mean±SD of triplicate
samples
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reduced the viability to 12.3 %, while H2-60 and H2-57
reduced viability to 14 and 17.1 %, respectively. The propor-
tion of viable cells in the biofilms treated with vancomycin
(128 mg/l) was 88.6 %, similar to that of 0.1 % DMSO
(Fig. 4).
Cytotoxicity and hemolytic activity of the derivatives
When the derivatives at six different concentrations up to
200 μM were added onto Vero cells and incubated for 24 h
at 37 °C, the formation of formazan in the MTT viability
assay was inhibited by less than 3 %. The CC50 values of
all the derivatives were therefore greater than 200 μM
higher than that of the parent prototype compound
(50 μM Cells treated with 0.1 % DMSO showed no
cytotoxicity (Table 1).
At theMIC concentrations, all six derivatives lysed healthy
human erythrocytes by less than 1 %, while the prototype
compound 2 produced 2.31±0.35 % hemolysis (Table 2).
Even at the highest concentrations (200 μM), all of the deriv-
atives gave no obvious hemolysis, whereas compound 2 gave
5.24 % hemolysis.
Antimicrobial efficacy of the derivatives in a rabbit
subcutaneous S. epidermidis biofilm infection model
We evaluated antibiofilm activities of H2-74 and H2-81
in vivo using a rabbit subcutaneous S. epidermidis biofilm
infection model. When 24-h-old biofilms of S. epidermidis on
polyethylene disks were implanted subcutaneously and ex-
posed for 72 h to either H2-74 or H2-81 at 4×MIC, bacterial
viability was substantially reduced compared to DMSO or
vancomycin controls (Fig. 5). CFUs in biofilms treated with
H2-74 were reduced to 2.91±0.42 log10 CFU/cm2 and H2-81
to 2.18 log10 CFU/cm2 (p<0.05, n=6), whereas the CFUs in
the 0.1 % DMSO-treated biofilms were 5.3±0.15 log10 CFU/
cm2, and in the vancomycin-treated biofilms, 5.21±0.24
log10 CFU/cm2.
Table 2 Anti-Staphylococcus ac-
tivities of the derivatives
aMIC, which represents minimal
inhibitory concentration of the
derivatives, was determined by
the broth dilution (in tubes)
method according to the standards
of CLSI of the USA
b The derivatives did not inhibit
the growth of E. coli ATCC
25922, even at the highest con-
centration used in the experiment
c MIC values for compound 2

















Compound 2c 25 50 50 25–50 25–50 >200
H2-38 1.5 1.5 1.5 1.5–3.1 1.5–3.1 >200
H2-39 1.5 1.5 1.5 1.5–3.1 1.5–3.1 >200
H2-57 3.1 1.5 3.1 1.5–3.1 1.5–3.1 >200
H2-60 1.5 1.5 1.5 1.5–3.1 1.5–3.1 >200
H2-74 1.5 1.5 3.1 3.1–6.3 3.1–6.3 >200
H2-81 1.5 1.5 1.5 1.5 1.5 >200
Fig. 3 SEM of biofilms treated with the derivatives H2-74 or H2-81. An
overnight culture of S. epidermidis ATCC 35984 was inoculated into
polystyrene 96-well plates and incubated for 6 h. Then, DMSO,
vancomycin (128 mg/l), or 4×MIC of H2-74 and H2-81 was added into
each well and incubated for 16 h. The biofilm samples were fixed with
gluteraldehyde and observed by SEM
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Discussion
Many new compounds with antibacterial activities have been
discovered through structure-activity studies and library
screening using the core scaffold of potential targets. These
include inhibitors targeting the kinase activities of YycF and
YycG (Watanabe et al. 2003). The YycFG TCS or its
orthologs (also referred as WalRK) (Dubrac et al. 2007) have
been found in most low G+C gram-positive bacteria, includ-
ing many important pathogens. They play important roles in
regulating bacterial murein and exopolysaccharide biosynthe-
sis, biofilm formation, cell division, and virulence factor ex-
pression (Bisicchia et al. 2007; Dubrac and Msadek 2004; Ng
et al. 2003; Winkler and Hoch 2008). Inhibitors against YycG
or YycF are bactericidal for gram-positive pathogens (Okada
et al. 2010). It has been reported that the inhibitors walkmycin
B that targets YycG and walrycin A/B that targets YycF are
effective against Bacillus subtilis and S. aureus at low MICs,
though efficacy against biofilms has not been described
(Okada et al. 2010; Watanabe et al. 2003).
Fig. 4 Bactericidal effect of derivatives on mature biofilms of
S. epidermidis observed by CLSM. Overnight cultures of S. epidermidis
ATCC 35984 were inoculated into FluoroDishes and incubated at 37 °C
for 24 h, and then the biofilms were treated with derivatives at concen-
trations of 4×MIC for another 16 h. The biofilms were visualized by
CLSM with Live/Dead BacLight viability staining (SYTO9/PI). Cells
stained with green fluorescence are viable and with red fluorescence are
dead. The images of three-dimensional biofilm structure were created by
IMARIS 7.0.0 software. The percentages of green bacteria in total bac-
teria were calculated by ImageJ using the intensity of green fluorescence
divided by that of total fluorescence
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In previous studies, we have found two leading compounds
(compound 2 and compound 5) that target YycG and have
antibiofilm activities against S. epidermidis (Qin et al. 2006).
To improve the antibacterial activities of compound 2, we
designed and synthesized a series of derivatives, keeping the
thiazolidione core structure intact (Huang et al. 2012; Pan
et al. 2010). Here, the anti-staphylococcal activities of 56 of
the newly synthesized derivatives were tested, and six showed
higher antibacterial activities (MIC ranged from 1.5 to
6.3 μM) than the leading compound 2 (MIC=25 μM) and
H2-28 (MIC=3.1 μM) than previously reported (Huang et al.
2012). These six new derivatives exhibited antimicrobial ac-
tivities against both MSRE andMSRA clinical isolates. All of
them have halogen substituents (F or Cl) on phenyl rings of
the thiazolidine core structure, indicating that introducing
halogen elements maintained or improved the potent antibac-
terial activity of compound 2.
The six derivatives, especially H2-57, H2-74, and H2-81,
were bactericidal against S. epidermidis cells in mature
biofilms, and their antibiofilm activities have been improved
compared to that of compound 2 and the derivatives studied
previously (H2-10, H2-12, H2-20, H2-27, H2-28, H2-29)
(Huang et al. 2012). At the highest concentration of the
derivatives used in this study (200 μM), no cytotoxicity or
hemolytic activities were observed. Furthermore, in the rabbit
subcutaneous S. epidermidis biofilm infection model, the
tested derivatives (H2-74 and H2-81) reduced bacterial via-
bility, indicating their potential efficacy against clinical bio-
film infection in vivo.
AlthoughH2-74 and H2-81 showed the same bacteriostatic
activities (MIC=1.5 μM), they had different bactericidal
efficacy; when S. epidermidis planktonic cells were treated
with H2-81 at the concentration of 4×MIC for 10 h only,
~10 CFU remained, while for H2-74, 3.2×102 CFU were
detected. Consistent with this, the IC50 of H2-74 (71.2 μM)
was higher than that of H2-81 (24.2 μM). Comparison of the
two derivatives’ structures shows that H2-74 contains a 4-
phenoxy-acid fragment while H2-81 bears a 3-(5-thiophene-
2-yl) benzoic acid fragment. The incorporation of a 2-
phenylfuran moiety could enhance antibacterial activity of
compounds (Ashok et al. 2007), and furan rings had been
introduced into the derivatives H2-38, H2-39, and H2-57,
which also displayed potent antibacterial activities and inhib-
itory effect on the phosphorylation of the YycG′ protein. The
furan moiety was replaced with thiophene based on
bioisosterism in H2-60 and H2-81, and both structures
showed similar antibacterial activity and inhibitory effect on
the phosphorylation of the YycG′ protein. This indicates that
incorporation of a furan or thiophene ring and introducing
halogen elements in the appropriate position may improve the
antibacterial activities of the derivatives.
Combination antimicrobial therapy is widely used to take
advantage of different mechanisms of action. It may potentiate
the effect of individual antimicrobial agents by synergic action
(Bijnsdorp et al. 2011; Cokol et al. 2011). The glycopeptide
antibiotics, such as vancomycin, can bind the peptidoglycan
side chains in the cell wall and prevent cross-linking during
cell wall synthesis. Vancomycin has been considered to be one
of the most reliable therapeutic agents against staphylococcal
infections, but it is unable to clear biofilms even at high
concentration (128 mg/l) (Climo et al. 1999; Darouiche et al.
1994; Tenover et al. 2001). Cefazolin has been used to treat
various bacterial infections worldwide since the 1970s, and it
can competitively inhibit the transpeptidases known as
penicillin-binding proteins (PBPs) in the final transpeptidation
step of the synthesis of peptidoglycan. YycGF also plays an
important role in the synthesis of peptidoglycan in B. subtilis
and S. aureus (Bisicchia et al. 2007; Dubrac and Msadek
2004). In a preliminary study, we assessed the effects of the
combined application of the derivatives with vancomycin and
cefazolin against S. epidermidisATCC 35984 according to the
method of Odds (2003) (Cottagnoud et al. 2003). A synergis-
tic effect on S. epidermidis was observed when H2-81 was
combined with vancomycin or cefazolin. No antagonism was
observed between the derivatives and vancomycin or
cefazolin (Table S1). These observations suggested that the
derivatives may be used either alone or in association with
other antibiotics. The potential synergistic effects in drug
combinations warrant further investigation with clinical staph-
ylococcal strains and multiresistant isolates.
Biofilms are highly resistant to clearance by most antimi-
crobial therapies because of the complicated multicellular
architecture (Kittinger et al. 2011). The subcutaneous foreign
body infection animal models are established for studying the
Fig. 5 The viable bacteria recovered from the implanted disks in rabbit
subcutaneous S. epidermidis infection model. The effects of H2-74 and
H2-81 on 24-h biofilms of S. epidermidis ATCC 35984 were tested in a
rabbit subcutaneous S. epidermidis infection model. Biofilm-covered
polyethylene disks were implanted in subcutaneous cavities and exposed
to H2-74 (6.3 μM, 4×MIC) or H2-81 (6.3 μM, 4×MIC) by three intra-
cavity injections at 24-h intervals. Vancomycin (128 mg/l) and 0.1 %
DMSO were administered as controls. Twenty-four hours after the last
treatment, the implants were taken out and viable bacteria on the disks
were determined by CFU counting. Y-axis represents the number of
S. epidermidis CFU; each dot in the figure represents the count of viable
cells from one disk. Data were analyzed by ANOVA with Bonferroni’s
multiple comparison test; *p<0.05 and ***p<0.001 (n=12)
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effect of remedies on medical device-related biofilms, including
mice, rat, and rabbit models (Coenye andNelis 2010). Compared
with other subcutaneous foreign body biofilm infection models,
rabbit models are easy to manipulate and can be treated with
different derivatives at the same time to reduce individual differ-
ences. In the present study, we used the rabbit subcutaneous
S. epidermis biofilm infection models to evaluate the antibiofilm
efficacy of the derivatives in vivo. After the treatment of H2-74
and H2-81 locally, CFUs in the biofilms were significantly
reduced compared with untreated controls. This is in concor-
dance with antibiofilm efficacy in vitro.
In summary, the bactericidal and antibiofilm activities of
the six newly designed derivatives of YycG inhibitors are
improved compared to prototype compound 2. However, the
antimicrobial efficacy of derivatives should be further im-
proved by additional modification of the compound struc-
tures. Studies of the toxicity in vivo and of the preclinical
druggability of the derivatives will also be needed before there
might be clinical application against biofilm-associated infec-
tions and multidrug-resistant bacterial infections.
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